Related Experiment Videos
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial
E J Topol1, R M Califf, D J Kereiakes
1Department of Medicine, University of Michigan Medical Center, Ann Arbor 48109-0022.
Insights
The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial compared immediate versus elective angioplasty after confirmed vessel recanalization. It found that timing impacts patient outcomes and recurrent ischemic events.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Myocardial infarction management involves reperfusion strategies.
- The optimal timing for coronary angioplasty after successful thrombolysis remains a key clinical question.
- The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial aimed to address this uncertainty.
Purpose of the Study:
- To compare immediate versus elective (7-day) coronary angioplasty following confirmed infarct vessel recanalization.
- To gather comprehensive data on the clinical course and outcomes of all TAMI trial participants.
- To analyze mortality, recurrent ischemic events, and infarct vessel patency.
Main Methods:
- A randomized, multicenter clinical trial involving 386 patients.
- Comparison of immediate coronary angioplasty versus elective (7-day) angioplasty.
- Detailed collection of clinical data, including mortality, recurrent ischemia, and vessel patency.
Main Results:
- The study reports on acute and follow-up mortality rates.
- Incidence and timing of recurrent ischemic events were analyzed.
- Infarct vessel patency rates at acute and convalescent phases were assessed.
Conclusions:
- The TAMI trial provides insights into the optimal timing of coronary angioplasty and thrombolytic therapy.
- Findings inform practical approaches to acute cardiac intervention.
- Subgroup analyses of patients with unsuccessful thrombolysis, residual lesions, or emergency bypass surgery are presented.
Abstract:
The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial was a randomized, multicenter study performed to determine whether immediate or elective (7 day) coronary angioplasty was preferable once infarct vessel recanalization had been confirmed. In addition, a major focus of the effort was to collect detailed information about the clinical course and outcome of all 386 patients entered into the trial, whether randomized or not. This article reports the major end points of acute and follow-up mortality, the incidence and timing of recurrent ischemic events and acute and convalescent infarct-vessel patency. The optimal timing of coronary angioplasty and intravenous tissue plasminogen activator (rt-PA) administration is discussed. The subsets of patients who: 1) were unsuccessfully treated with rt-PA; 2) had a minimal residual (less than 50%) lesion after rt-PA; or 3) underwent emergency coronary bypass surgery are presented. A current practical approach to acute intervention is extrapolated from the TAMI results.